A recent report on the global human reproductive technologies market has been published by Transparency Market Research. The report, titled “Human Reproductive Technologies Market – Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 – 2019,” projects this market to expand at a CAGR of 2.20% during the period from 2013 to 2019. The market is estimated to stand at a valuation of US$27.1 bn by 2019.According to the World Health Organization, in 2010, about 1.9% of the female population worldwide in the age group of 20-44 years was unable to conceive the first child. The growing prevalence of infertility has been attributed to a number of environmental and socio-economic factors. The various human reproductive technologies have witnessed increasing popularity in the past couple of years for the treatment of infertility among both men and women.
Request a PDF Brochure with Report Analysis:
With the rise in female employment, there has been a growing trend of a delay in conception. Factors such as pollution, smoking, stress, and obesity have led to an increase in infertile population. The growing prevalence of unwanted pregnancies, initiatives taken by governments and NGOs to promote contraceptive products, and the implementation of favorable policies such as the Affordable Care Act has propelled the growth of the global human reproductive technologies market.
However, limited insurance coverage and the side effects of contraceptive drugs and devices might hamper the growth of the market during the forecast period. The global human reproductive technologies market has a significant opportunity to grow with the rise in medical tourism, government support for the treatment of infertility, and the presence of a strong pipeline of contraceptive drugs.
The market for contraceptives stood at a valuation of US$16 bn in 2012. During the forecast period, the market is estimated to expand at a CAGR of 5.5%. In 2012, the oral contraceptives segment witnessed the highest demand due to the availability of contraceptives as an over-the-counter drug.
The key regions in the global human reproductive technologies market are Europe, Asia Pacific, North America, and Rest of the World. In 2012, North America emerged as the leading region in the market, followed by Europe. North America is predicted to dominate the market throughout the forecast period. However, the market is projected to register the fastest growth in Asia Pacific due to the increasing awareness about contraceptives, high population density, and rise in disposable income.
Some of the major players in the global human reproductive technologies market are Bayer AG, Abbott Laboratories, Actavis Inc., Boston Scientific Corporation, Church & Dwight Co. Inc., Merck KGaA, Warner Chilcott plc, Reckitt Benckiser Group plc, Merck Serono, Pfizer Inc., Johnson & Johnson, Cook Medical Inc., and Teva Pharmaceutical Industries Ltd. The report discusses some of the key attributes of the market players including their business strategies, product portfolio, and recent developments. Through a SWOT analysis, the report identifies the future growth opportunities for the market vendors.
Browse Research Report on Global Human Reproductive Technologies Market: